RPRX compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

RPRXRoyalty Pharma plc

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

RPRXRoyalty Pharma plc

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

RPRX

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±5.4%▲+0.47%×0.09

Q1 FY26—▲+0.56%—

Feb 11 '26—▲+0.09%—

Q3 FY25—▲+6.82%—

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedRPRX realized, solidLLY realized, hatchedOne scale, both sides: full bar = 11%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

RPRXRoyalty Pharma plc

67.19▲+0.01%· post 66.62

Mkt cap$38.2BRevenue$674MQ2 FY26Revenue$2.4BFY25

LLYELI Lilly & Co

1,418.01▲+0.03%· post 1,412.00

ClosedNov 2 '26

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 2 '26

RPRXRoyalty Pharma plc

LLYELI Lilly & Co

67.19▲+0.01%post 66.62

Price

1,418.01▲+0.03%post 1,412.00

$38.2B

Mkt cap

$1.3T

Q2 FY26$674M

Revenue

$24.4BQ3 FY26

FY25$2.4B

Revenue

$65.2BFY25

RPRX67.19▲+0.01%vsLLY1,418.01▲+0.03%ClosedNov 2 '26